Literature DB >> 1988127

In vivo activity of solid phase interleukin 2.

E D Crum1, D R Kaplan.   

Abstract

Interleukin 2 (IL-2) coupled to polystyrene beads to form a solid phase of the cytokine was able to increase the cytotoxic activity of rat spleen cells in vitro. A single injection of the IL-2 coupled beads into the peritoneal cavities of normal rats also resulted in the in vivo activation of cytotoxicity of peritoneal exudate cells, whereas a single i.p. injection of the same amount of soluble IL-2 was not effective. When IL-2 coupled beads were mixed with methylcholanthrene-induced Mc7 or Mc107 sarcoma cells and injected into normal syngeneic Wistar rats, the growth of the tumor was suppressed. This effect was localized to the site of the injection. The in vivo activities were achieved with modest amounts of IL-2, less than has been previously reported to be well tolerated in rodents. IL-2 coupled to a solid matrix may be useful for delivering increased concentrations of the lymphokine to tumor dominant regions while maintaining low systemic levels and thereby increasing the therapeutic index.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988127

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Biological activity of interleukin-2 bound to Candida albicans.

Authors:  C B Treseler; R T Maziarz; S M Levitz
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 3.  Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.

Authors:  R A Maas; H F Dullens; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 4.  Effects of route and formulation on clinical pharmacokinetics of interleukin-2.

Authors:  P M Anderson; M A Sorenson
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.